Abstract
Ozet: Lenfomalarin akciger tutulum sekilleri 3 tipe ayrilabilir: mediastinal, parankimal ve plevral. Pulmoner parankimal tutulum Hodgkin lenfomada non-Hodgkin lenfomaya gore daha sik rapor edilmektedir. Calismaya dahil edilen 700 lenfoma tanili hastamizin 40’inda akciger tutulumu saptandi. Hastalarin 27’si erkek, 13’u kadin olup yaslari 18 ile 80 arasinda idi. 40 hastanin 31’i NHL, 9’u HL olup hastalarda en sik gorulen akciger tutulum tipi parankimal tutulum idi. Akciger tutulum tipleri ile evre, risk skoru, yasam suresi, ex orani ve ECOG performansi arasinda istatistiksel fark saptanmadi. Hasta grubumuzda median yasam suresi 22-25 ay arasinda saptandi. Akciger tutulumu olan lenfoma hastalarimiz genellikle ileri evre hastalardi. Hasta grubumuzda akciger tutulumu tipi (mediastinal- parankimal ve plevral) yasam suresini etkilememektedir ancak bu hastalarda mortalite oranlari yuksektir. Anahtar kelimeler: Lenfoma, akciger tutulumu, prognoz LUNG INVOLVEMENT AND THE RELATIONSHIP WITH PROGNOSIS IN PATIENT WITH LYMPHOMA: A SINGLE CENTER EXPERIENCE Abstarct: Lung involvement type in lymphoma, can be classified into 3 types: mediastinal, parenchymal and pleural. Pulmonary parenchymal involvement in lymphoma is reported more commonly in Hodgkin’s disease than non-Hodgkin’s lymphoma. Seven hundred patients diagnosed with lymphoma were enrolled in the study. Fourty patients were diagnosed with lung involvement (31 were NHL and 9 were HL). There were 27 male and 13 female patients, aging from 18 to 80 years. The most common lung involvement type was parenchymal involvement. There were no correlation between lung involvement type and stage, risk score, overall survival, mortality and ECOG performance score. The median survival time was 22-25 months in our patient group. Our lymphoma patients with lung involvement were usually at advanced stage. In our patient group, type of lung involvement (mediastinal- parenchymal-pleural) did not effect the survival time but the mortality rate in these patients were high. Keywords: Lymphoma, lung involvement, prognosis
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
